Pioglitazone

From Ganfyd

Revision as of 23:07, 10 June 2011 by Mlj (Talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
rINN: Pioglitazone
Other Names
Actos®
Pharmacological Information
Pharmacology Images
Pioglitazone molecule
Pioglitazone.png
Web information on Pioglitazone
NHS Evidence on Pioglitazone
DrugBank on Pioglitazone
Mechanism of Action
  • Reduce peripheral insulin resistence
Other Issues for Pioglitazone
  • The oedema induced in renal or heart failure can be remarkably diuretic resistent unless drug stopped.
  • Increased fracture risk in women
    • Relevant Clinical Literature
    Pubmed on Pioglitazone
    RCT with Pioglitazone
    Systematic reviews of Pioglitazone
    Pioglitazone in N Eng J Med, Lancet, JAMA, BMJ
    Pioglitazone in Cochrane Collaboration
    TRIP Database on Pioglitazone
    Google Scholar on Pioglitazone
    Bandolier on Pioglitazone
    UK Guidance
    Nice Guidance on Pioglitazone

    BNF-registration required
    BNF for children-registration required

    UK directory of medicines
    UK Medicine Guide (eg pictures of capsules)
    Centre for Reviews and Dissemination databases -DARE & NHS EED (evaluates reliability of research)
    Prodigy Guidance on Pioglitazone
    Regulatory Literature
    UK SPCs of medicines with marketing authorisation
    EMEA search
    FDA search
    Other Literature
    PubChem on Pioglitazone
    CTD (Comparative Toxicogenomics Database) link
    ChemIndustry.com link
    Protein Structural Information
    Biological Information (GenomeNet)
    Protein Knowledgebase (UniProtKB)
    Please read pharmacological data limitations
    Other Wikis
    Medpedia on Pioglitazone (Less technical, good quality control)
    Wikipedia on Pioglitazone (Less technical, ? quality control)

    Contents

    Introduction

    Clinical Use

    The nature of the licensing process based of surrogate outcomes means that there are still information gaps that mean the clinical risk benefit ratio is not fully understood. This also applies to any other medication that has entered the diabetic market in the last 10 years. By the middle of 2011 sufficient evidence of an association with bladder cancer had arisen[1] that national regulators started withdrawing marketing authorization[2].

    Indications

    Possible indications

    Administration

    Oral

    Clinical Issues

    Contra-indications

    • Renal failure
    • Heart failure

    Cautions and Interactions

    Side effects

    Class side effects

    Possible Association

    • Bladder cancer in long term use[1]

    Special advice

    Pharmacology

    References

    1. ↑ a b Risque de cancer de la vessie chez les personnes diabétiques traitées par pioglitazone en France : une étude de cohorte sur les données du SNIIRAM et du PMSI Caisse nationale de l’assurance maladie, Paris, France. Rapport final du 7/06/2011 accessed 10 June 2011
    2. ↑ Update on ongoing European review of pioglitazone–containing medicines EMEA accessed 10 June 2011
    Retrieved from "http://www.ganfyd.org/index.php?title=Pioglitazone"
    Personal tools